Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Iconovo ABOSTO:ICO -1.66%37 Net-Net Working Capital is kr0.35 as of Mar. 2026. GuruFocus rates OSTO:ICO with a GF Score™ of 37/100 and a GF Value™ of kr0.26 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 421 Medical Devices & Instruments companies, Iconovo AB ranks better than 80.29% on this metric.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Iconovo AB's Net-Net Working Capital for the quarter that ended in Mar. 2026 was kr0.35.
The industry rank for Iconovo AB's Net-Net Working Capital or its related term are showing as below:
OSTO:ICO's Price-to-Net-Net-Working-Capital is ranked better than 80.29% of 421
companies
in the Medical Devices & Instruments industry
Industry Median: 6.59
vs OSTO:ICO: 2.71
Iconovo AB (OSTO:ICO) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Iconovo AB Net-Net Working Capital Related Terms
Iconovo AB Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for Iconovo AB's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ICO vs ABT, SYK, MDT: Net-Net Working Capital Comparison
For the Medical Devices subindustry, Iconovo AB's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Iconovo AB Price-to-Net-Net-Working-Capital vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Iconovo AB's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Iconovo AB's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of kr0.35 mean?
Iconovo AB (OSTO:ICO) has a Net-Net Working Capital of kr0.35 as of Mar. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Iconovo AB According to the industry distribution chart, Iconovo AB ranks #83 out of 421 companies in the Medical Devices & Instruments industry, placing it in the top 19.7%.
Is Iconovo AB's Net-Net Working Capital too high?
Iconovo AB's current Net-Net Working Capital is kr0.35. Based on the distribution chart, Iconovo AB ranks #83 out of 421 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Iconovo AB has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Iconovo AB's Net-Net Working Capital compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Iconovo AB ranks #83 out of 421 companies for Net-Net Working Capital. This places Iconovo AB in the top 20% of its industry — outperforming the majority of peers. The industry median Net-Net Working Capital is 6.59. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Medical Devices & Instruments company?
The median Net-Net Working Capital among Medical Devices & Instruments companies is 6.59, based on 421 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Iconovo AB For the Medical Devices & Instruments industry, the median Net-Net Working Capital is 6.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Iconovo AB's current Net-Net Working Capital is kr0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iconovo AB stock overvalued right now?
Based on GuruFocus' analysis, Iconovo AB (OSTO:ICO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.26, compared to a current price of kr0.95 — trading 264.6% above its estimated fair value. The current Net-Net Working Capital is kr0.35. Iconovo AB's overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Iconovo AB (OSTO:ICO), the current Net-Net Working Capital is kr0.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Iconovo AB (OSTO:ICO) Overvalued in 2026?
Based on GuruFocus' analysis, Iconovo AB stock appears to be overvalued.
The current stock price of kr0.95 is trading 264.6% above its estimated GF Value™ of kr0.26.
GuruFocus considers Iconovo AB to be Significantly Overvalued.
Key valuation signals for OSTO:ICO:
Net-Net Working Capital: kr0.35
GF Value™: kr0.26 vs. price of kr0.95 (264.6% above fair value)
No single metric tells the full story. See the OSTO:ICO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iconovo AB develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The project is a generic version of the asthma and COPD product Symbicort.
37GF Score
Get the complete analysis for OSTO:ICO
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ICO has been successfully added to your 
